Genentech’s First Quarter Solid, Avastin Slow
This article was originally published in The Pink Sheet Daily
Executive Summary
Breast-cancer push not yet in full swing, company says.
You may also be interested in...
Rituxan For Lupus Misses Primary, Secondary Endpoints
Widely anticipated EXPLORER data prove disappointing in the wake of PPMS failure.
Rituxan For Lupus Misses Primary, Secondary Endpoints
Widely anticipated EXPLORER data prove disappointing in the wake of PPMS failure.
Avastin Misses Overall-survival Endpoint In Lung Cancer
Analysts expect minimal damage to sales as a result of AVAiL data.